Danaher Corporation $DHR Shares Sold by Korea Investment CORP

Korea Investment CORP trimmed its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 456,678 shares of the conglomerate’s stock after selling 4,551 shares during the quarter. Korea Investment CORP owned 0.06% of Danaher worth $90,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. White Pine Capital LLC increased its holdings in shares of Danaher by 1.4% during the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after acquiring an additional 49 shares in the last quarter. Boyd Watterson Asset Management LLC OH grew its position in Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after purchasing an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC grew its position in Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after purchasing an additional 53 shares during the last quarter. 1834 Investment Advisors Co. increased its stake in Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 54 shares in the last quarter. Finally, Bruce G. Allen Investments LLC raised its holdings in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after buying an additional 54 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on DHR shares. Redburn Partners set a $220.00 price objective on shares of Danaher in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft lifted their price target on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. TD Cowen increased their price objective on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Finally, Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $243.39.

Danaher Price Performance

NYSE:DHR opened at $228.41 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The company has a 50 day moving average price of $210.88 and a 200-day moving average price of $202.81. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The firm has a market cap of $161.33 billion, a price-to-earnings ratio of 47.09, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business earned $1.71 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s payout ratio is currently 26.39%.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.